A major obstacle in the treatment of acute myeloid leukemia (AML) is refractory disease or
relapse after achieving remission. The latter arises from a few therapy-resistant cells within …

Evidence of human acute myeloid leukemia stem cells (AML LSCs) was first reported nearly
2 decades ago through the identification of rare subpopulations of engrafting cells in …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

Immune cells infiltrating tumors can have important impact on tumor progression and
response to therapy. We present an efficient algorithm to simultaneously estimate the …

The emerging" epitranscriptomics" field is providing insights into the biological and
pathological roles of different RNA modifications. The RNA methyltransferase METTL1 …

Patients with acute myeloid leukaemia (AML) often achieve remission after therapy, but
subsequently die of relapse that is driven by chemotherapy-resistant leukaemic stem cells …

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS)
are life-threatening hyperferritinemic systemic inflammatory disorders. Although profound …

Background Deconvolution analyses have been widely used to track compositional
alterations of cell types in gene expression data. Although a large number of novel methods …

RNA-binding proteins (RBPs) are essential modulators of transcription and translation
frequently dysregulated in cancer. We systematically interrogated RBP dependencies in …

The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently
transforming acute myeloid leukemia (AML) therapy. However, there is a lack of clinically …